We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi, Regeneron Modify Kevzara Trial After Preliminary Results Fall Short
Sanofi, Regeneron Modify Kevzara Trial After Preliminary Results Fall Short
Sanofi and Regeneron have modified their clinical trial of the rheumatoid arthritis drug Kevzara (sarilumab) as a COVID-19 treatment after preliminary results found no benefit in one group.